Phio Pharmaceuticals Corp. (PHIO) stock
PHIONasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.77−0.04 (-5.03%)
Close on Nov 13, 2026Market cap $8.96MP/E –Yield –
Phio Pharmaceuticals r&d expenses
Research and development expenses are spending on new products and technology.
Phio Pharmaceuticals's R&D Expenses for the twelve months ending Sep 30, 2026 was $10.41M, up 152.4% year over year. For fiscal 2025 it was $4.62M, up 26.8% from the year before. Over ten years it grew -4.0% a year on average. The highest annual figure on record is $17.65M in fiscal 2013.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.62M | +26.8% |
| FY2024 | Dec 31, 2024 | $3.64M | -42.5% |
| FY2023 | Dec 31, 2023 | $6.33M | -9.7% |
| FY2022 | Dec 31, 2022 | $7.01M | -21.1% |
| FY2021 | Dec 31, 2021 | $8.89M | +139.1% |
| FY2020 | Dec 31, 2020 | $3.72M | -13.6% |
| FY2019 | Dec 31, 2019 | $4.30M | -0.6% |
| FY2018 | Dec 31, 2018 | $4.33M | -19.4% |
| FY2017 | Dec 31, 2017 | $5.37M | -0.8% |
| FY2016 | Dec 31, 2016 | $5.42M | -21.8% |
| FY2015 | Dec 31, 2015 | $6.93M | +21.9% |
| FY2014 | Dec 31, 2014 | $5.68M | -67.8% |
| FY2013 | Dec 31, 2013 | $17.65M | +68.9% |
| FY2012 | Dec 31, 2012 | $10.45M | +57.8% |
| FY2011 | Dec 31, 2011 | $6.62M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $3.06M | +159.3% |
| Q2 FY2026 | Jun 30, 2026 | $3.08M | +187.0% |
| Q1 FY2026 | Mar 31, 2026 | $2.79M | +215.2% |
| Q4 FY2025 | Dec 31, 2025 | $1.48M | +49.9% |
| Q3 FY2025 | Sep 30, 2025 | $1.18M | +83.4% |
| Q2 FY2025 | Jun 30, 2025 | $1.07M | +24.0% |
| Q1 FY2025 | Mar 31, 2025 | $886.00K | -22.8% |
| Q4 FY2024 | Dec 31, 2024 | $985.00K | -2.2% |
| Q3 FY2024 | Sep 30, 2024 | $644.00K | -64.4% |
| Q2 FY2024 | Jun 30, 2024 | $866.00K | -37.4% |
| Q1 FY2024 | Mar 31, 2024 | $1.15M | -46.2% |
| Q4 FY2023 | Dec 31, 2023 | $1.01M | -37.6% |
| Q3 FY2023 | Sep 30, 2023 | $1.81M | -27.9% |
| Q2 FY2023 | Jun 30, 2023 | $1.38M | +6.1% |
| Q1 FY2023 | Mar 31, 2023 | $2.13M | +34.6% |
| Q4 FY2022 | Dec 31, 2022 | $1.61M | -27.5% |
| Q3 FY2022 | Sep 30, 2022 | $2.51M | -6.2% |
| Q2 FY2022 | Jun 30, 2022 | $1.30M | -16.4% |
| Q1 FY2022 | Mar 31, 2022 | $1.59M | -34.7% |
| Q4 FY2021 | Dec 31, 2021 | $2.23M | +380.6% |
| Q3 FY2021 | Sep 30, 2021 | $2.67M | +112.8% |
| Q2 FY2021 | Jun 30, 2021 | $1.56M | +100.1% |
| Q1 FY2021 | Mar 31, 2021 | $2.43M | +99.4% |
| Q4 FY2020 | Dec 31, 2020 | $463.00K | -54.7% |
| Q3 FY2020 | Sep 30, 2020 | $1.26M | +20.5% |
| Q2 FY2020 | Jun 30, 2020 | $779.00K | -32.0% |
| Q1 FY2020 | Mar 31, 2020 | $1.22M | +11.8% |
| Q4 FY2019 | Dec 31, 2019 | $1.02M | +8.4% |
| Q3 FY2019 | Sep 30, 2019 | $1.04M | +24.3% |
| Q2 FY2019 | Jun 30, 2019 | $1.15M | -3.1% |
| Q1 FY2019 | Mar 31, 2019 | $1.09M | -20.0% |
| Q4 FY2018 | Dec 31, 2018 | $944.00K | -21.6% |
| Q3 FY2018 | Sep 30, 2018 | $838.00K | -43.8% |
| Q2 FY2018 | Jun 30, 2018 | $1.18M | -11.0% |
| Q1 FY2018 | Mar 31, 2018 | $1.36M | +1.0% |
| Q4 FY2017 | Dec 31, 2017 | $1.20M | -7.9% |
| Q3 FY2017 | Sep 30, 2017 | $1.49M | – |
| Q2 FY2017 | Jun 30, 2017 | $1.33M | – |
| Q1 FY2017 | Mar 31, 2017 | $1.35M | – |
| Q4 FY2016 | Dec 31, 2016 | $1.31M | – |
See a number that looks wrong?